Impact of Catheter Ablation on Arrhythmia Burden in Patients With Shock-Resistant Persistent Atrial Fibrillation.

atrial tachyarrhythmia burden catheter ablation implantable cardiac monitor persistent atrial fibrillation quality of life

Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
10 2023
Historique:
received: 03 08 2022
revised: 30 05 2023
accepted: 07 06 2023
medline: 27 10 2023
pubmed: 6 8 2023
entrez: 5 8 2023
Statut: ppublish

Résumé

Persistent shock-resistant atrial fibrillation (AF) is a challenging entity, with modest results from catheter ablation according to conventional survival analysis. The aim of this study was to determine the effect of catheter ablation on atrial tachyarrhythmia (ATA) burden in persistent AF patients undergoing first-time ablation with the use of an implantable cardiac monitor (ICM). Patients with drug-resistant ongoing persistent AF and at least 1 previous failed cardioversion were implanted with an ICM 2 months before the procedure. All patients underwent pulmonary vein isolation with or without additional substrate ablation depending on the presence of self-terminating AF on ICM and left atrium size. Median AF burden before and after ablation, off antiarrhythmic medication, was determined from ICM recordings after review by 2 independent investigators. Sixty patients were recruited (mean age 66 ± 9 years, 70% male). Mean left atrial diameter was 48 ± 6 mm and median CHA Patient-tailored catheter ablation results in a significant reduction in ATA burden (off antiarrhythmic medication) in shock-resistant persistent AF patients using ICMs implanted 2-months pre-procedure. These data suggest that conventional arrhythmia-free survival analysis does not capture the true impact of catheter ablation in this challenging cohort.

Sections du résumé

BACKGROUND
Persistent shock-resistant atrial fibrillation (AF) is a challenging entity, with modest results from catheter ablation according to conventional survival analysis.
OBJECTIVES
The aim of this study was to determine the effect of catheter ablation on atrial tachyarrhythmia (ATA) burden in persistent AF patients undergoing first-time ablation with the use of an implantable cardiac monitor (ICM).
METHODS
Patients with drug-resistant ongoing persistent AF and at least 1 previous failed cardioversion were implanted with an ICM 2 months before the procedure. All patients underwent pulmonary vein isolation with or without additional substrate ablation depending on the presence of self-terminating AF on ICM and left atrium size. Median AF burden before and after ablation, off antiarrhythmic medication, was determined from ICM recordings after review by 2 independent investigators.
RESULTS
Sixty patients were recruited (mean age 66 ± 9 years, 70% male). Mean left atrial diameter was 48 ± 6 mm and median CHA
CONCLUSIONS
Patient-tailored catheter ablation results in a significant reduction in ATA burden (off antiarrhythmic medication) in shock-resistant persistent AF patients using ICMs implanted 2-months pre-procedure. These data suggest that conventional arrhythmia-free survival analysis does not capture the true impact of catheter ablation in this challenging cohort.

Identifiants

pubmed: 37542487
pii: S2405-500X(23)00390-0
doi: 10.1016/j.jacep.2023.06.004
pii:
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2071-2081

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Louisa O'Neill (L)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium. Electronic address: louisa.oneill@kcl.ac.uk.

Alexandre Almorad (A)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Milad El Haddad (M)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Jean-Yves Wielandts (JY)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Kris Gillis (K)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Gabriela Hilfiker (G)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Benjamin de Becker (B)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Michelle Lycke (M)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Rene Tavernier (R)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Jean-Benoit le Polain de Waroux (JB)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Mattias Duytschaever (M)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Sebastien Knecht (S)

Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH